Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

18,003 recalls, newest first

Risk Class IClass IIClass III
Status OngoingCompletedTerminated
Year 20262025202420232022 All years
Cause Sterility / contaminationNitrosamine impurityChemical / undeclaredParticulate / foreign matterLabeling / mix-upcGMP deviationMicrobial contamination All causes
Class I · High risk

REUMOFAN PLUS Tablets

Marketed Without an Approved NDA/ANDA; Product contains undeclared diclofenac and methocarbamol.

Terminated Chemical / undeclared Pain Free By Nature D-1322-2014
Class II · Moderate risk

Perrigo

Presence of Particulate Matter Perrigo is recalling seven lots of Clindamycin Palmitate Hydrochloride for Oral Solution 75mg/5ml.

Terminated Particulate / foreign matter Paddock Laboratories, LLC NDC 0574-0129-01 D-1168-2014
Class II · Moderate risk

Lupron Depot

Defective Delivery System: Some Lupron Depot Kits may containin a syringe with a potentially defective LuproLoc needle stick protection device.

Terminated Packaging defect AbbVie Inc NDC 0074-3642-03 D-1291-2014
Class II · Moderate risk

Lupron Depot

Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device.

Terminated Packaging defect AbbVie Inc NDC 0074-3663-03 D-1290-2014
Class II · Moderate risk

Lupron Depot-Ped

Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device.

Terminated Packaging defect AbbVie Inc NDC 0074-3779-03 D-1289-2014
Class II · Moderate risk

Lupron Depot

Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device.

Terminated Packaging defect AbbVie Inc NDC 0074-3473-03 D-1288-2014
Class II · Moderate risk

Lupron Depot

Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device.

Terminated Packaging defect AbbVie Inc NDC 0074-3346-03 D-1287-2014
Class I · High risk

Venlafaxine HCl Extended-Release Capsules

Presence of Foreign Tablets/Capsules: report of a foreign capsule with markings (TKN 250) and identified as a Tikosyn (dofetilide) capsule was found in a bottle of Effexor XR (venlafaxine HCl) 150 mg capsules that was packaged in the same packaging campaign as the recalled lot

Terminated Particulate / foreign matter Greenstone Llc NDC 59762-0182-2 D-1361-2014
Class I · High risk

Effexor XR

Presence of Foreign Tablets/Capsules: A Pharmacist reported that a bottle of Effexor XR 150 mg capsules contained a single peach colored capsule printed TKN250 which was identified as a Tikosyn (dofetilide) capsule.

Terminated Particulate / foreign matter Pfizer Us Pharmaceutical Group NDC 0008-0836-21 D-1328-2014
Class II · Moderate risk

Duloxetine Delayed-Release Capsules

Failed Tablet/Capsule Specifications: Teva Pharmaceuticals USA, is voluntarily recalling certain lots of Duloxetine DR Capsules USP, 20 mg, 30 mg & 60 mg due to a customer complaint trend regarding capsule breakage.

Terminated Failed specification Teva Pharmaceuticals USA NDC 0093-7544-56 D-1184-2014
Class II · Moderate risk

Duloxetine Delayed-Release Capsules

Failed Tablet/Capsule Specifications: Teva Pharmaceuticals USA, is voluntarily recalling certain lots of Duloxetine DR Capsules USP, 20 mg, 30 mg & 60 mg due to a customer complaint trend regarding capsule breakage.

Terminated Failed specification Teva Pharmaceuticals USA NDC 0093-7543-56 D-1183-2014
Class II · Moderate risk

Duloxetine Delayed-Release Capsules

Failed Tablet/Capsule Specifications: Teva Pharmaceuticals USA, is voluntarily recalling certain lots of Duloxetine DR Capsules USP, 20 mg, 30 mg & 60 mg due to a customer complaint trend regarding capsule breakage.

Terminated Failed specification Teva Pharmaceuticals USA NDC 0093-7542-06 D-1182-2014
Class III · Low risk

Ritalin HCl

Labeling: Incorrect or Missing Package Insert; The back of the Medication Guide attached to the Package Insert for Ritalin Tablets was printed with information related to Ritalin SR (Sustained Release) Tablets. Both products, Ritalin Tablets and Ritalin SR Tablets utilize a combined Package Insert. The individual Medication Guides are attached to the Package Insert via a perforation. Although t

Terminated Labeling / mix-up Novartis Pharmaceuticals Corp. NDC 0078-0441-05 D-1228-2014
Class III · Low risk

Ritalin HCl

Labeling: Incorrect or Missing Package Insert; The back of the Medication Guide attached to the Package Insert for Ritalin Tablets was printed with information related to Ritalin SR (Sustained Release) Tablets. Both products, Ritalin Tablets and Ritalin SR Tablets utilize a combined Package Insert. The individual Medication Guides are attached to the Package Insert via a perforation. Although t

Terminated Labeling / mix-up Novartis Pharmaceuticals Corp. NDC 0078-0440-05 D-1227-2014

Recalls by year